Novartis to face PD1 competition for Mekinist and Tafinlar combo
This article was originally published in Scrip
Executive Summary
The $20bn Novartis-GSK mega deal has brought the Swiss firm new opportunities this week as the European Medicines Agency announced CHMP positive opinions for Tafinlar (dabrafenib) and Mekinist (trametinib) as well as Revoldade (eltrombopag). However, Datamonitor Healthcare believes that sales of the melanoma combo in unlikely to be transformational for the market or the company thanks to pricing pressures and competition from anti-PD1s.